These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1135 related articles for article (PubMed ID: 3948300)
1. In vitro comparative studies of the myelotoxicity and antitumor activity of 6-[bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose versus melphalan utilizing the CFU-C and HTSCA assays. Lazarus P; Dufour M; Isabel G; Panasci LC Cancer Chemother Pharmacol; 1986; 16(2):148-52. PubMed ID: 3948300 [TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and bone marrow toxicity of aminoglucose mustard anticancer agents in mice. Cantrell JE; Green D; Schein PS Cancer Res; 1986 May; 46(5):2340-3. PubMed ID: 2938728 [TBL] [Abstract][Full Text] [Related]
3. 6-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride (C6-galactose mustard), a new alkylating agent with reduced bone marrow toxicity. Schein PS; Green D; Dean SW; McPherson E Cancer Res; 1987 Feb; 47(3):696-9. PubMed ID: 3802075 [TBL] [Abstract][Full Text] [Related]
4. Effects of amino acids on the transport and cytotoxicity of melphalan by human bone marrow cells and human tumor cells. Dufour M; Panasci LC; St Germain J; Boulet L Cancer Chemother Pharmacol; 1985; 15(2):125-31. PubMed ID: 4017161 [TBL] [Abstract][Full Text] [Related]
5. Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human glioma compared with BCNU. Panasci LC; Dufour M; Chevalier L; Isabel G; Lazarus P; McQuillan A; Arbit E; Brem S; Feindel W Cancer Chemother Pharmacol; 1985; 14(2):156-9. PubMed ID: 3971480 [TBL] [Abstract][Full Text] [Related]
6. Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosoureas. Ali-Osman F; Giblin J; Berger M; Murphy MJ; Rosenblum ML Cancer Res; 1985 Sep; 45(9):4185-91. PubMed ID: 2411398 [TBL] [Abstract][Full Text] [Related]
7. Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development. Fiebig HH; Schmid JR; Bieser W; Henss H; Lohr GW Eur J Cancer Clin Oncol; 1987 Jul; 23(7):937-48. PubMed ID: 3665999 [TBL] [Abstract][Full Text] [Related]
8. Selective cytotoxicity of a system L specific amino acid nitrogen mustard. Haines DR; Fuller RW; Ahmad S; Vistica DT; Marquez VE J Med Chem; 1987 Mar; 30(3):542-7. PubMed ID: 3820226 [TBL] [Abstract][Full Text] [Related]
9. 6-bis-(2-chloroethyl)amino-6-deoxy-D-galactopyranose hydrochloride: synthesis, chemical characterization, murine P388 antitumor activity, and bone marrow toxicity. Schein PS; Green D; Hammer CF; McPherson E; Talebian A J Pharm Sci; 1989 Nov; 78(11):918-21. PubMed ID: 2621574 [TBL] [Abstract][Full Text] [Related]
10. Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow. Robinson BA; Clutterbuck RD; Millar JL; McElwain TJ Br J Cancer; 1985 Dec; 52(6):813-22. PubMed ID: 4074636 [TBL] [Abstract][Full Text] [Related]
11. Amino acid conferred protection against melphalan: comparison of amino acids which reduce melphalan toxicity to murine bone marrow precursor cells (CFU-C) and murine L1210 leukemia cells. Vistica DT; Rabon A; Rabinovitz M Res Commun Chem Pathol Pharmacol; 1979 Jan; 23(1):171-83. PubMed ID: 441510 [TBL] [Abstract][Full Text] [Related]
12. In vitro studies with melphalan and pediatric neoplastic and normal bone marrow cells. Worthington-White DA; Graham-Pole JR; Stout SA; Riley CM Int J Cancer; 1986 Jun; 37(6):819-23. PubMed ID: 3458679 [TBL] [Abstract][Full Text] [Related]
13. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy. Siemann DW; Beyers KL Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357 [TBL] [Abstract][Full Text] [Related]
14. Preclinical activity of 17 beta-[N-[N'-(2-chloroethyl)-N'-nitrosocarbamoyl]-L-alanyl]-5 alpha-dihydrotestosterone (E91) against tumour colony forming units and haematopoietic progenitor cells. Rank P; Peter R; Depenbrock H; Eisenbrand G; Schmid P; Pitzl H; Hanauske AR Eur J Cancer; 1999 Jun; 35(6):1009-13. PubMed ID: 10533486 [TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo anticancer activity of mitozolomide and sparsomycin in human tumor xenografts, murine tumors and human bone marrow. Fiebig HH; Berger DP; Köpping K; Ottenheijm HC; Zylicz Z J Cancer Res Clin Oncol; 1990; 116(6):550-6. PubMed ID: 2254373 [TBL] [Abstract][Full Text] [Related]
16. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors. Lemoli RM; Gulati SC Exp Hematol; 1990 Oct; 18(9):1008-12. PubMed ID: 2397748 [TBL] [Abstract][Full Text] [Related]
17. Sensitivity of human and murine hemopoietic precursor cells to chemotherapeutic agents assessed in cell culture. Ogawa M; Bergsagel DE; McCulloch EA Blood; 1973 Dec; 42(6):851-6. PubMed ID: 4759912 [No Abstract] [Full Text] [Related]
18. Anticancer activity of bisphosphonic acids in methylnitrosourea-induced mammary carcinoma of the rat--benefit of combining bisphosphonates with cytostatic agents. Wingen F; Pool BL; Klein P; Klenner T; Schmähl D Invest New Drugs; 1988 Sep; 6(3):155-67. PubMed ID: 3056867 [TBL] [Abstract][Full Text] [Related]
19. A circadian variation of melphalan (L-phenylalanine nitrogen mustard) toxicity to murine bone marrow: relevance to cancer treatment protocols. Simpson HW; Stoney PJ Br J Haematol; 1977 Mar; 35(3):459-64. PubMed ID: 870008 [TBL] [Abstract][Full Text] [Related]
20. Correlation of nitrosourea murine bone marrow toxicity with deoxyribonucleic acid alkylation and chromatin binding sites. Green D; Tew KD; Hisamatsu T; Schein PS Biochem Pharmacol; 1982 May; 31(9):1671-9. PubMed ID: 7104031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]